Company Interview / Decades in the making, a breath away from the world's biggest market

James McBrayer, chief executive and managing director of Cyclopharm (ASX: CYC) , outlines how the company is scaling the US rollout of its Technegas lung-imaging technology following FDA approval. McBrayer states that the United States represents the company's single largest growth opportunity, opening a market that had effectively been closed to the product for decades, which he views as transformational for the business.

McBrayer explains that Cyclopharm has begun securing hospital-network agreements, including a multi-site rollout with a major US hospital system, and points to a maximum US patent extension that protects Technegas into the next decade. He says the company has reported record first-half revenue, and frames the US expansion as building on an established and profitable international base across Europe and other markets.

Looking ahead, McBrayer says the priorities include accelerating Technegas installations across US hospitals as international clinical guidelines are finalised, deepening relationships with large hospital networks, and sharpening the company's focus on the imaging business following the divestment of its cyclotron asset. He adds that Cyclopharm (ASX:CYC) is balancing the pace of its US investment against the goal of building durable, recurring revenue from each installed site.

*partner content